

Health and Wellbeing Board Paper

1. Reference information

Paper tracking information	
Title:	Surrey Pharmaceutical Needs Assessment Supplementary Statement 2021
Related Health and Wellbeing Priority:	Statutory responsibility of the Health and Wellbeing Board
Authors:	Authors: Rachel Abbey, Lynne Sawyer, Public Health Analysts (SCC) Reviewer and Approver: Dr Naheed Rana, Consultant in Public Health (SCC)
Sponsor:	Ruth Hutchinson, Director of Public Health (SCC)
Paper date:	4 March 2021
Related papers	Annex 1: Surrey Pharmaceutical Needs Assessment: Supplementary Statement – March 2021 2018 Pharmaceutical Needs Assessment (PNA) and 2020 PNA Supplementary statement (Available on www.surrey-i.gov.uk)

10

2. Executive summary

The Surrey Health and Wellbeing Board (HWB) has a statutory responsibility to deliver a Pharmaceutical Needs Assessment (PNA) every three years. The PNA was delayed from 2020 to 2021 due to resources being diverted to the Covid-19 pandemic. The full Surrey PNA was last published in March 2018. This is regularly supplemented by the PNA Steering Group which reviews changes to the local population and local services annually to ensure that no substantive changes to the Pharmaceutical Needs Assessment are required. The attached report (Annex 1) provides a supplementary statement to the 2021 Pharmaceutical Needs Assessment which reports no substantive changes are required to the findings of the 2018 Pharmaceutical Needs Assessment.

3. Recommendations

1. The Board is asked to approve the 2021 Pharmaceutical Needs Assessment Supplementary Statement, on the advice of the Pharmaceutical Needs Assessment Steering Group.
2. The Board is asked to publish the approved Supplementary Statement on surrey-i.gov.uk and surreycc.gov.uk by 31 March 2021.

4. Reason for Recommendations

The Surrey Pharmaceutical Needs Assessment Steering Group has met to discuss findings in the 2021 Pharmaceutical Needs Assessment Supplementary Statement and have agreed the supplementary statement for approval and publication by the Health and Wellbeing Board.

5. Detail

Policy and Governance Framework

Health and Wellbeing Boards were given responsibility from 2013 for delivering a Pharmaceutical Needs Assessment (PNA) for their area. The PNA determines the local need

for pharmaceutical services. The PNA is used principally to inform decisions on whether to allow new pharmaceutical services in a given area (a process called market entry) based on that need. NHS England is responsible for those commissioning decisions. The Surrey PNA, which uses Integrated Care Partnership geographies, can also be used to support the work of local clinical commissioning groups around primary care, the management of long-term conditions, and urgent and emergency care.

The 2013 NHS (Pharmaceutical Services and Local Pharmaceutical Services) Regulations set out the legislative basis for developing and updating PNAs. HWBs are required to publish a revised assessment every 3 years. Following the introduction of these regulations in Surrey, the first PNA was published in Surrey in March 2015 and the second in March 2018, the next full PNA was due to be published by April 2021. In 2020 it was agreed to implement a 1-year delay in the PNA (delayed until 2022) due to Covid-19 response.

Pending the publication of the 2022 Pharmaceutical Needs Assessment, the HWB may publish a supplementary statement explaining changes to the availability of pharmaceutical services relevant to the granting of applications and where the HWB is satisfied that making a revised statement would be a disproportionate response to those changes. The 2021 supplementary statement is expected to become part of the 2022 PNA. In Surrey, we review the PNA annually to determine if a full revision is required and, if not, publish a supplementary statement.

The Surrey HWB delegated responsibility for delivering the Surrey Pharmaceutical Needs Assessment (PNA) to the PNA Steering Group, now chaired by Dr Naheed Rana, Public Health Consultant.

The responsibilities of the PNA Steering Group are:

- a) Ensure the PNA project objectives are clear, defined in the PNA Project Initiation Document (PID), for the initial PNA and PNA revisions
- b) Provide executive approval and sign-off of high-level project documentation and plans for the PNA project
- c) Agree quality criteria for all aspects of the PNA project
- d) Undertake executive reviews of the performance and monitor progress against plans for the PNA project
- e) Ensure the business, executive, clinical, user and technical perspectives are fully represented
- f) Resolve any conflicts between business, clinical, user and technical requirements, priorities and preferences
- g) Ensure the final products shown in the PID are delivered on schedule.
- h) Make recommendations as to agreed tolerances (with respect to time and scope) and at-risk activities
- i) Endorse sign off for each project stage and authorise continuation to the next stage as stated in the PNA PID and timeline.
- j) Ensure all relevant guidance and policies are followed, and ensure probity at all times
- k) Ensure the PNA is utilised to influence commissioning
- l) Communicate with key stakeholders about the PNA

2021 PNA Supplementary Statement

The PNA Steering Group met on 29th January 2021 to review changes to the local population and to pharmaceutical provision since the publication of the Surrey PNA 2018 and the 2019 and 2020 Supplementary Statement.

The Steering Group agreed that the changes to demographic need and pharmaceutical provision were minimal and that the supplementary statement outlining identified changes was sufficient until work on the full 2022 PNA commences. The attached 2021 PNA Supplementary Statement details the changes to pharmacy provision and services and the conclusion reached.

2022 full PNA

Planning for the next full PNA has started; this will be published by 1st April 2022. Discussions are being held with representatives of the healthcare system, including members of the Primary Care Transformation Board, to consider how the PNA could support the aims of the NHS Long Term Plan and the primary care transformation in Surrey. Discussions with planning officers in the local District and Boroughs will also be used to inform how the PNA process can be utilised to support the planning of pharmacy provision for future large-scale housing developments within Surrey.

6. Challenges

The process for determining the PNA Supplementary Statement is robust and therefore risks are minimal for this part of the process.

There remains one issue to be resolved as part of the 2022 PNA; this relates to challenge between the way in which planning takes account of the need for health infrastructure, especially in new large-scale housing developments (needs based on future build) and the way in which the PNA determines the need for market entry for community pharmacies (need for the current population). One additional challenge to delivery of the 2022 PNA is to secure the required data from stakeholders in a timely way.

7. Timescale and delivery plan

An outline plan for delivery of the 2022 PNA has been developed and will be refined based on discussions with local health and care partners. The draft report should be completed by September 2021 with consultation on the report taking place in October and November 2021. Further redrafting required from the feedback received will take place in December 2021 under the guidance of the PNA Steering Group. The final 2022 PNA report is due for completion in January 2022. This final report will be submitted to the HWB for approval by March 2022.

8. How is this being communicated?

The Health and Wellbeing Board Communications Group have been advised of the consultation related to the 2022 PNA.

9. Next steps

If the Health and Wellbeing Board approves the 2021 Supplementary Statement, it will be published by 31 March on surreycc.gov.uk and surreyi.gov.uk websites.

The PNA Steering Group will meet at critical points in the delivery of the 2022 PNA to approve actions to date and escalate any issues. An in-year PNA progress report can be provided to the HWB, if required.

This page is intentionally left blank